Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.
Laura Bucher-Bailey, PharmD
Advertisement
Articles by Laura Bucher-Bailey, PharmD
Advertisement
Latest Updated Articles
Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical CancerPublished: September 25th 2024 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
Progress in the Treatment of Advanced-Stage Classical Hodgkin Lymphoma in the PET-Adapted Era
3
CRT Does Not Improve RFS/OS, Confers High-Grade Toxicity in Cervical Cancer
4
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
5
